

From the Chief Medical Officer
Dr Michael McBride



Department of
Health

An Roinn Sláinte

Mánnystrie O Poustie

www.health-ni.gov.uk

HSS(MD) 4/2019

For Action:

Chief Executives of HSC Trusts
GP Medical Advisers, Health and Social Care Board
All General Practitioners and GP Locums (for onward distribution to practice staff)
Director of Integrated Care, Health and Social Care Board
Assistant Director of Pharmacy and Medicines Management, Health and Social Care Board (for onward distribution to Community Pharmacies)

Castle Buildings
Stormont Estate
BELFAST
BT4 3SQ

Tel: 028 90 520559

Fax: 028 90 520573

Email: Michael.McBride@health-ni.gov.uk

Our Ref: HSS(MD) 4/2019

Date: 22 March 2019

PLEASE SEE ATTACHED FULL CIRCULATION LIST

Dear Colleague

FLUOROQUINOLONE ANTIBIOTICS: NEW RESTRICTIONS AND PRECAUTIONS DUE TO VERY RARE REPORTS OF DISABLING AND POTENTIALLY LONG LASTING OR IRREVERSIBLE SIDE EFFECTS

This letter is to inform you that following an EU wide review of safety, new restricted indications are being introduced for fluoroquinolone antibiotics (Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin) that are available in the UK. The review found that systemic (by mouth, injection or inhalation) fluoroquinolones can very rarely cause long lasting (up to months or years), disabling, and potentially irreversible side effects affecting musculoskeletal (including tendonitis and tendon rupture) and nervous systems.

Advice for healthcare professionals:

- Prescribers and dispensers of fluoroquinolones should advise patients to stop treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice – see [MHRA sheet](#) to discuss measures with patients. Available at: <https://assets.publishing.service.gov.uk/media/5c9364c6e5274a48edb9a9fa/FQ-patient-sheet-final.pdf>

- Fluoroquinolone treatment should be discontinued at the first sign of tendon pain or inflammation in patients and the affected limb or limbs appropriately treated (for example with immobilisation)
- Fluoroquinolones should no longer be prescribed for:
 - Non-severe or self-limiting infections, or non-bacterial conditions
 - Mild to moderate infections (such as in acute exacerbation of chronic bronchitis and chronic obstructive pulmonary disease) unless other antibiotics that are commonly recommended for these infections are considered inappropriate*
 - Uncomplicated cystitis (for which ciprofloxacin or levofloxacin were previously authorised) unless other antibiotics that are commonly recommended are considered inappropriate*

*For example, when first-line antibiotics are unsuitable due to resistance, contraindications, or intolerance, or if first-line treatments have failed

- Avoid use of a corticosteroid with a fluoroquinolone since co-administration could exacerbate fluoroquinolone-induced tendinitis and tendon rupture
- Avoid use of fluoroquinolones in patients who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic
- Prescribe fluoroquinolones with special caution in people older than 60 years and for those with renal impairment or solid-organ transplants because they are at a higher risk of tendon injury
- Report suspected adverse drug reactions to fluoroquinolone antibiotics on the [Yellow Card website](#) or via the Yellow Card app (download it from the [Apple App Store](#), or [Google Play Store](#))

Please refer to the attached communication from MHRA for further information.

Yours sincerely



pp. DR MICHAEL McBRIDE
Chief Medical Officer



MRS CATHY HARRISON
Acting Chief Pharmaceutical Officer

Circulation List

Executive Medical Director/Director of Public Health, Public Health Agency (for onward distribution to all relevant staff)

Director of Nursing, Public Health Agency
Directors of Pharmacy HSC Trusts
Director of Social Care and Children, HSCB
Family Practitioner Service Leads, Health and Social Care Board (for cascade to GP Out of Hours services)
Medical Directors, HSC Trusts (for onward distribution to all Consultants, gynaecology, hepatology, A&E staff, hospital pharmacy, and sexual health/family planning centres)
Nursing Directors, HSC Trusts (for onward distribution to all Community Nurses, and Midwives)
RQIA (for onward transmission to all independent providers including independent hospitals)
Medicines Management Pharmacists, HSC Board (for cascade to prescribing advisers)
Regional Medicines Information Service, Belfast HSC Trust
Regional Pharmaceutical Procurement Service, Northern HSC Trust
Professor Donna Fitzsimons, Head of School of Nursing and Midwifery QUB
Professor Sonja McIlfattrick, Head of School of Nursing, University of Ulster
Caroline Lee, CEC
Donna Gallagher, Open University
Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, UU
Professor Carmel Hughes, Head of School, School of Pharmacy, QUB
Professor Colin Adair, Director of the NI Centre for Pharmacy Learning and Development, QUB

This letter is available on the Department of Health website at
<https://www.health-ni.gov.uk/topics/professional-medical-and-environmental-health-advice/hssmd-letters-and-urgent-communications>



21 March 2019

DDL_fluoroquinolones_March-2019

Fluoroquinolone antibiotics: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin

New restrictions and precautions due to very rare reports of disabling and potentially long-lasting or irreversible side effects

- Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal (including tendonitis and tendon rupture) and nervous systems have been reported with fluoroquinolone antibiotics – see [Drug Safety Update](#) for more information
- Prescribers and dispensers of fluoroquinolones should advise patients to stop treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice – see [MHRA sheet to discuss measures with patients](#)
- Fluoroquinolone treatment should be discontinued at the first sign of tendon pain or inflammation in patients and the affected limb or limbs appropriately treated (for example with immobilisation)

Fluoroquinolones should **not** be prescribed for:

- non-severe or self-limiting infections, or non-bacterial conditions
- mild to moderate infections (such as in acute exacerbation of chronic bronchitis and chronic obstructive pulmonary disease) unless other antibiotics that are commonly recommended for these infections are considered inappropriate*
- uncomplicated cystitis (for which ciprofloxacin or levofloxacin were previously authorised) unless other antibiotics that are commonly recommended are considered inappropriate*

*For example, when first-line antibiotics are unsuitable due to resistance, contraindications, or intolerance, or if first-line treatments have failed.

- Avoid coadministration with corticosteroids since this could exacerbate fluoroquinolone-induced tendinitis and tendon rupture
- Avoid use in patients who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic
- Prescribe with special caution in people older than 60 years and for those with renal impairment or solid-organ transplants because they are at a higher risk of tendon injury

Page | 1 of 2



Medicines & Healthcare products
Regulatory Agency



Trigger for the advice on fluoroquinolones

An EU review of the safety fluoroquinolone and quinolone antibiotics was triggered by reports of disabling and potentially long-lasting, irreversible side effects mainly affecting the musculoskeletal and nervous systems. See [Drug Safety Update](#) for characteristics of reactions reported.

The review identified 286 cases of serious adverse reactions reported as disabling and lasting for 30 days or more, without any alternative explanations, from across the EU over a 21-year period. Although cumulative fluoroquinolone patient exposure data are not available for this time period, it is estimated that more than 300 million daily doses of fluoroquinolone antibiotics are dispensed every year in the EU.

Although relatively few cases have been reported, under-reporting is likely. Due to the seriousness of these reactions sometimes reported in previously healthy people, any decision to prescribe a fluoroquinolone should be taken after a careful assessment of the benefits and risks in each case.

If fluoroquinolones are to be used, prescribers should ensure they consult the Summary of Product Characteristics and national guidance, and inform patients of the actions they should take at the first signs of a serious adverse reaction.

Report any suspected adverse event reactions to fluoroquinolones to the Yellow Card Scheme online (<https://yellowcard.mhra.gov.uk/>) or the Yellow Card App (download via [iTunes Yellow Card](#) for iOS devices or via [PlayStore Yellow Card](#) for Android devices).

Nalidixic acid

The quinolone nalidixic acid was authorised for urinary tract infections, which is no longer a permitted indication. Therefore, the licence for nalidixic acid has been cancelled.

Yours sincerely,

Dr June Raine

Director, Vigilance and Risk Management of Medicines (VRMM) Division,
MHRA
info@mhra.gov.uk